http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Sep 2025 08:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pelthos+Therapeutics++++++For%3A+Sep+02/25289030.html si-local-file:///var/storage/secattach/20250903/25289030.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pelthos+Therapeutics++++++For%3A+Sep+02/25289030.html Wed, 03 Sep 2025 08:31:00 -0400 CHRO http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Pelthos+Therapeutics+++++++++++++++++/25269733.html si-local-file:///var/storage/secattach/20250828/25269733.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Pelthos+Therapeutics+++++++++++++++++/25269733.html Thu, 28 Aug 2025 16:06:00 -0400 CHRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pelthos+Therapeutics++++++For%3A+Aug+18/25216369.html si-local-file:///var/storage/secattach/20250818/25216369.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pelthos+Therapeutics++++++For%3A+Aug+18/25216369.html Mon, 18 Aug 2025 08:06:00 -0400 CHRO http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pelthos+Therapeutics+++++++++++++++++++Filed+by%3A+AME+Equities+LLC/25198249.html si-local-file:///var/storage/secattach/20250813/25198249.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Pelthos+Therapeutics+++++++++++++++++++Filed+by%3A+AME+Equities+LLC/25198249.html Wed, 13 Aug 2025 18:24:00 -0400 CHRO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Pelthos+Therapeutics++++++For%3A+Jun+30/25197216.html si-local-file:///var/storage/secattach/20250813/25197216.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Pelthos+Therapeutics++++++For%3A+Jun+30/25197216.html Wed, 13 Aug 2025 16:40:00 -0400 CHRO http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Pelthos+Therapeutics+++++++++++++++++/25101368.html si-local-file:///var/storage/secattach/20250725/25101368.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Pelthos+Therapeutics+++++++++++++++++/25101368.html Fri, 25 Jul 2025 17:26:00 -0400 CHRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pelthos+Therapeutics++++++For%3A+Jul+02++Filed+by%3A+Plesha+Scott+M./25089856.html si-local-file:///var/storage/secattach/20250723/25089856.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pelthos+Therapeutics++++++For%3A+Jul+02++Filed+by%3A+Plesha+Scott+M./25089856.html Wed, 23 Jul 2025 21:17:00 -0400 CHRO http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Pelthos+Therapeutics++++++For%3A+Jul+02++Filed+by%3A+Plesha+Scott+M./25089852.html si-local-file:///var/storage/secattach/20250723/25089852.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Pelthos+Therapeutics++++++For%3A+Jul+02++Filed+by%3A+Plesha+Scott+M./25089852.html Wed, 23 Jul 2025 21:14:00 -0400 CHRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pelthos+Therapeutics++++++For%3A+Jul+02++Filed+by%3A+Rangarao+Sai/25076890.html si-local-file:///var/storage/secattach/20250721/25076890.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Pelthos+Therapeutics++++++For%3A+Jul+02++Filed+by%3A+Rangarao+Sai/25076890.html Mon, 21 Jul 2025 20:27:00 -0400 CHRO http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Pelthos+Therapeutics++++++For%3A+Jul+02++Filed+by%3A+Rangarao+Sai/25076888.html si-local-file:///var/storage/secattach/20250721/25076888.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Pelthos+Therapeutics++++++For%3A+Jul+02++Filed+by%3A+Rangarao+Sai/25076888.html Mon, 21 Jul 2025 20:26:00 -0400 CHRO http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Pelthos+Therapeutics+++++++++++++++++/25039231.html si-local-file:///var/storage/secattach/20250710/25039231.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Pelthos+Therapeutics+++++++++++++++++/25039231.html Thu, 10 Jul 2025 16:15:00 -0400 CHRO http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Press+Releases/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Globe+Newswire/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Globe+Newswire/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Globe+Newswire/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Globe+Newswire/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS http://www.streetinsider.com/Globe+Newswire/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html <ul><li style="text-align:justify;">ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies</li><li style="text-align:justify;">Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician&apos;s office, at home or on the go</li><li style="text-align:justify;">Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children<br/></li></ul> <p align="justify">DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company http://www.streetinsider.com/Globe+Newswire/Pelthos+Therapeutics+Launches+ZELSUVMI%E2%84%A2+%28berdazimer%29+Topical+Gel+10.3%25%2C+the+First+and+Only+FDA-Approved+At-Home+Treatment+for+Molluscum+Contagiosum/25036186.html Thu, 10 Jul 2025 08:00:00 -0400 A.00796151 A.06822034 A.09642568 A.60012013 CHRO O.20026344 O.20371933 O.38236026 O.40299161 O.66524547 PTHS